Inter-viit Intraocular Preure Range: An Alternative Parameter for Aeing Intraocular Preure Control in Clinical Trial Original Reearch Article

Purpoe To evaluate whether inter-viit intraocular preure (IOP) range, which reflect extreme and potentially damaging IOP fluctuation, provide additional information on IOP control compared to mean IOP. Deign Pot hoc analyi of Xalatan/Lumigan/Travatan tudy data, a maked-evaluator, randomized, parallel-group comparion of 12-week efficacy of latanoprot, bimatoprot, and travoprot in open-angle glaucoma/ocular hypertenion patient. Method Pretreatment inter-viit IOP range defined a highet IOP minu lowet IOP at creening, afety check, and baeline (ix meaurement); pottreatment inter-viit IOP range defined a highet IOP minu lowet IOP at week two, ix, and 12 or early termination (nine meaurement). Range dichotomized a “high” (>6 mm Hg) v “low” (≤6 mm Hg). Reult Included were 410 patient (latanoprot, 136; bimatoprot, 136; travoprot, 138). Each reulted in ignificant mean IOP range reduction during 12 week. Pretreatment inter-viit IOP range wa aociated with African-American race, male gender, and preence of viual field defect (P < .05 for all). Percentage with high pretreatment inter-viit IOP range were comparable acro treatment (63% to 64%). High pottreatment inter-viit IOP range wa een in 21% (28/136), 28% (38/136), and 36% (50/138) of latanoprot, bimatoprot, and travoprot group, repectively (P = .016, overall; P = .005, latanoprot v travoprot). High pottreatment inter-viit IOP range wa aociated with African-American race, high pretreatment inter-viit IOP range, and treatment with travoprot v latanoprot (P < .05 for all). Concluion Given that high inter-viit IOP range i aociated with rik factor for glaucomatou damage and that uch difference cannot be evaluated uing mean IOP, inter-viit IOP range may be another ueful approach to aeing IOP control in clinical trial.